A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation

PHASE2CompletedINTERVENTIONAL
Enrollment

383

Participants

Timeline

Start Date

April 13, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Chronic Constipation
Interventions
DRUG

ASP0456

oral

DRUG

Placebo

oral

Trial Locations (50)

Unknown

Site: 35, Aichi

Site: 36, Aichi

Site: 27, Chiba

Site: 28, Chiba

Site: 29, Chiba

Site: 30, Chiba

Site: 48, Fukuoka

Site: 49, Fukuoka

Site: 50, Fukuoka

Site: 1, Hokkaido

Site: 2, Hokkaido

Site: 45, Hyōgo

Site: 46, Hyōgo

Site: 47, Hyōgo

Site: 22, Kanagawa

Site: 23, Kanagawa

Site: 24, Kanagawa

Site: 25, Kanagawa

Site: 26, Kanagawa

Site: 44, Kyoto

Site: 37, Osaka

Site: 38, Osaka

Site: 39, Osaka

Site: 40, Osaka

Site: 41, Osaka

Site: 42, Osaka

Site: 43, Osaka

Site: 31, Saitama

Site: 32, Saitama

Site: 33, Saitama

Site: 34, Saitama

Site: 10, Tokyo

Site: 11, Tokyo

Site: 12, Tokyo

Site: 13, Tokyo

Site: 14, Tokyo

Site: 15, Tokyo

Site: 16, Tokyo

Site: 17, Tokyo

Site: 18, Tokyo

Site: 19, Tokyo

Site: 20, Tokyo

Site: 21, Tokyo

Site: 3, Tokyo

Site: 4, Tokyo

Site: 5, Tokyo

Site: 6, Tokyo

Site: 7, Tokyo

Site: 8, Tokyo

Site: 9, Tokyo

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT02425722 - A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation | Biotech Hunter | Biotech Hunter